Advanced Search
TAN Yi, LIU Yan, SONG Yuwei, CHEN Qiufang, TAN Guoqiang, GUI Xiujuan, LIN Shaoqiang. Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 783-788. DOI: 10.3971/j.issn.1000-8578.2016.09.011
Citation: TAN Yi, LIU Yan, SONG Yuwei, CHEN Qiufang, TAN Guoqiang, GUI Xiujuan, LIN Shaoqiang. Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 783-788. DOI: 10.3971/j.issn.1000-8578.2016.09.011

Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis

More Information
  • Corresponding author:

    LIN Shaoqiang, Email:shaotsiang@163.com

  • Received Date: November 23, 2015
  • Revised Date: January 12, 2016
  • Available Online: February 04, 2024
  • Objective 

    To systematically review the prognostic value of circulating tumor cells(CTCs) for metastatic prostate cancer patients by Meta-analysis.

    Methods 

    We electronically searched PubMed, EMbase, Cochrane Library, CNKI and CBM for collecting the studies about the prognostic relevance of CTCs in the peripheral blood of Gleason score 0-10th metastatic prostate cancer patients. The observation endpoint was the overall survival(OS). Review Manager 5.3 was used for this analysis.

    Results 

    A total of 10 studies involving 1 137 patients of metastatic prostate cancer were eligible for the final analyses. The results of Meta-analysis showed that the presence of CTCs was associated with OS(HR=2.47, 95%CI: 2.02-3.02, P<0.00001). According to the subgroup analysis by the detection time and the detection method, CTCs positive group show the poor prognosis than CTCs negative group patients. CTCs positive group showed a significantly positive correlation with the Gleason score of prostate cancer (OR=2.23, 95%CI: 1.41-3.53, P<0.04), rather than PSA or extra bone metastasis.

    Conclusion 

    CTCs is an adverse prognostic factor for metastatic prostate cancer patients, which is not significantly influenced by the detection time and check method.

  • [1]
    韩苏军, 张思维, 陈万青, 等. 中国前列腺癌发病现状和流行趋 势分析[J]. 临床肿瘤学杂志, 2013, 18(4): 330-4. [Han SJ, Zhang SW, Chen WQ, et al. Analysis of the status and trends of prostate cancer incidence in China[J]. Lin Chuang Zhong Liu Xue Za Zhi, 20 13, 18(4): 330-4.]
    [1]
    韩苏军, 张思维, 陈万青, 等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013, 18(4): 330-4. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201304013.htm

    Han SJ, Zhang SW, Chen WQ, et al. Analysis of the status and trends of prostate cancer incidence in China[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2013, 18(4): 330-4. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201304013.htm
    [2]
    Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease[J]. Eur Urol, 2011, 59(1): 61-7. doi: 10.1016/j.eururo.2010.10.039
    [2]
    Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease[J]. Eur Urol, 2011, 59(1): 61-7.
    [3]
    汤元佳, 何卫阳, 苟欣, 等. 循环肿瘤细胞在去势抵抗性前列腺癌中的应用进展[J]. 现代医药卫生, 2015, 31(15): 2287-9. http://www.cnki.com.cn/Article/CJFDTOTAL-XYWS201515019.htm

    Tang YJ, He WY, Gou X, et al. Progress of Circulating Tumor Cells in Castration-resistant Prostate Cancer[J]. Xian Dai Yi Yao Wei Sheng, 2015, 31(15): 2287-9. http://www.cnki.com.cn/Article/CJFDTOTAL-XYWS201515019.htm
    [3]
    汤元佳, 何卫阳, 苟欣, 等. 循环肿瘤细胞在去势抵抗性前列腺 癌中的应用进展[J]. 现代医药卫生, 2015, 31(15): 2287-9. [Tang YJ, He WY, Gou X, et al. Progress of Circulating Tumor Cells in Castration-resistant Prostate Cancer[J]. Xian Dai Yi Yao Wei Sheng, 2015, 31(15): 2287-9.]
    [4]
    Ashwoah TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J]. Aust Med J, 1869, 14: 146-9
    [4]
    Ashwoah TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J]. Aust Med J, 18 69, 14: 146-9.
    [5]
    胡玉倩, 谢圣高, 郑义, 等. 循环肿瘤细胞的富集与检测研究进展[J]. 肿瘤防治研究, 2014, 41(7): 834-8.

    Hu YQ, Xie SG, Zheng Y, et al. Review on Enrichment and Detection of Circulating Tumor Cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(7): 834-8.
    [5]
    胡玉倩, 谢圣高, 郑义, 等. 循环肿瘤细胞的富集与检测研究进展 [J] 肿瘤防治研究, 2014, 41(7): 834-8. [Hu YQ, Xie SG, Zheng Y, et al. Review on Enrichment and Detection of Circulating Tumor Cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(7): 834-8.]
    [6]
    Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells[J]. Cancer Res, 2013, 73(1): 8-11. doi: 10.1158/0008-5472.CAN-12-3422
    [6]
    Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells[J]. Cancer Res, 2013, 73(1): 8-11.
    [7]
    Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses[EB/OL]. [2013-11-26]. http://www.ohri.ca/programs/clinicalepidemiology/oxford.asp.
    [7]
    Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses[ EB/OL]. [2013-11-26]. http://www.ohri.ca/programs/ clinical epidemiology/oxford.asp.
    [8]
    Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase iii trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2014, 32(11): 1136-42. doi: 10.1200/JCO.2013.51.7417
    [8]
    Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase iii trial of docetaxel with or without atrasentan for metastatic castrationresistant prostate cancer[J]. J Clin Oncol, 2014, 32(11): 1136-42.
    [9]
    Thalgott M, Rack B, Eiber M, et al. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients[J]. BMC Cancer, 2015, 15: 458. doi: 10.1186/s12885-015-1478-4
    [9]
    Thalgott M, Rack B, Eiber M, et al. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients[J]. BMC Cancer, 2015, 15: 458.
    [10]
    Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell(CTC) counts as intermediate end points in castration-resistant prostate cancer(CRPC): a single-centre experience[J]. Ann Oncol, 20 09, 20(1): 27-33.
    [10]
    Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell(CTC) counts as intermediate end points in castration-resistant prostate cancer(CRPC): a single-centre experience[J]. Ann Oncol, 2009, 20(1): 27-33. http://cn.bing.com/academic/profile?id=2112564453&encoded=0&v=paper_preview&mkt=zh-cn
    [11]
    Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara, et al. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer[J]. Int J Urol, 2010, 17(15): 466-75. http://cn.bing.com/academic/profile?id=1524337669&encoded=0&v=paper_preview&mkt=zh-cn
    [11]
    Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara, et al. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer[J]. Int J Urol, 2010, 17(15): 466-75.
    [12]
    Resel Folkersma L, San José Manso L, Galante Romo I, et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer[J]. Urology, 2012, 80(6): 1328-32. doi: 10.1016/j.urology.2012.09.001
    [12]
    Resel Folkersma L, San José Manso L, Galante Romo I, et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer[J]. Urology, 20 12, 80(6): 1328-32.
    [13]
    Marín-Aguilera M, Reig Ò, lozano JJ, et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer[J]. Oncotarget, 2015, 6(12): 10604-16.
    [13]
    Marín-Aguilera M, Reig Ò, lozano JJ, et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer[J]. Oncotarget, 2015, 6(12): 10604-16. doi: 10.18632/oncotarget
    [14]
    Strijbos MH, Gratama JW, Schmitz PI, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel[J]. Eur J Cancer, 2010, 46(11): 2027-35. doi: 10.1016/j.ejca.2010.03.030
    [14]
    Strijbos MH, Gratama JW, Schmitz PI, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel[J]. Eur J Cancer, 2010, 46(11): 2027-35.
    [15]
    Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer[J]. J Urol, 2008, 180(4): 1342-7. doi: 10.1016/j.juro.2008.06.021
    [15]
    Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer[J]. J Urol, 2008, 180(4): 1342-7.
    [16]
    Okegawa T, Nutahara K, HigashiharaE, et al. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer[J]. J Urol, 2009, 181(3): 1091-7.
    [16]
    Okegawa T, Nutahara K, HigashiharaE, et al. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer[J]. J Urol, 2009, 181(3): 1091-7. doi: 10.1016/j.juro.2008.11.015
    [17]
    de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2008, 14 (19): 6302-9.
    [17]
    de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2008, 14(19): 6302-9. doi: 10.1158/1078-0432.CCR-08-0872
    [18]
    Hanaha D, Weinberg RA. Hallmarks of Cancer: the next generation[J]. Cell, 2011, 144(5): 646-74. doi: 10.1016/j.cell.2011.02.013
    [18]
    Hanaha D, Weinberg RA. Hallmarks of Cancer: the next generation [J] Cell, 2011, 144(5): 646-74.
    [19]
    朱玲, 向敏, 刘馨, 等. 循环肿瘤细胞临床应用的新进展[J]. 现代肿瘤学, 2014, 22(11): 2746-8. http://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201411078.htm

    Zhu L, Xiang M, Liu X, et al. Advances in Research on Circulating Tumor Cell[J]. Xian Dai Zhong Liu Xue, 2014, 22(11): 2746-8. http://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201411078.htm
    [19]
    朱玲, 向敏, 刘馨, 等. 循环肿瘤细胞临床应用的新进展[J]. 现 代肿瘤学, 2014, 22(11): 2746-8. [Zhu L, Xiang M, Liu X, et al. Advances in Research on Circulating Tumor Cell[J]. Xian Dai Zhong Liu Xue, 2014, 22(11): 2746-8.]
  • Related Articles

    [1]LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957
    [2]SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158
    [3]RAO Xionghui, LUO Hongliang, HUANG Jun, ZHU Zhengming. Prognostic and Clinicopathological Significance of PD-L1 Expression for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 1013-1021. DOI: 10.3971/j.issn.1000-8578.2019.19.0363
    [4]HU Ming, HUANG Xiaohong, ZUO Weiwei, ZHAO Jing. Clinicopathological and Prognostic Value of Circulating Tumor Cells in Peripheral Blood in Head and Neck Cancer Patients:A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 883-889. DOI: 10.3971/j.issn.1000-8578.2018.18.0407
    [5]ZHANG Tingting, WANG Xiangyi, GUO Ziwei, DING Xiaosheng, LIANG Jun. Prognostic Significance of Platelet-lymphocyte Ratio in Hepatocellular Carcinoma Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 775-780. DOI: 10.3971/j.issn.1000-8578.2018.18.0151
    [6]CUI Gang, YAN Bin, TAO Yongguang. Effect of FDG-PET/CT in Diagnosis, Staging and Prognosis of Pancreatic Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 202-208. DOI: 10.3971/j.issn.1000-8578.2017.03.010
    [7]Zheng, Wang Shuyi, Xiong Bin. Meta-analysis on Association of Circulating Tumor Cells with Prognosis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1139-1145. DOI: 10.3971/j.issn.1000-8578.2012.09.021
    [8]ZHENG Gang, WANG Shu-yi, XIONG Bin. Meta-analysis on Association of HER2-neu Expression with Prognosis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(10): 1173-1177. DOI: 10.3971/j.issn.1000-8578.2011.10.021
    [9]LV Peng, HU Zhi-jian. A Meta Analysis on Relationship between Alcohol Dehydrogenase2 Polymorphisms and Risk of Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 579-583. DOI: 10.3971/j.issn.1000-8578.2011.05.027
    [10]QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025

Catalog

    Article views (1751) PDF downloads (394) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return